Clinical Trial Update: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study of NKX019, a CD19 CAR-NK cell therapy, for Systemic Lupus Erythematosus, which has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• NKX019

Snippet

Sponsor: Columbia University | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: SUSPENDED